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Diaphragm weakness in mechanically ventilated
critically ill patients
Gerald S Supinski*† and Leigh Ann Callahan†

Abstract
Introduction: Studies indicate that mechanically ventilated patients develop significant diaphragm muscle
weakness, but the etiology of weakness and its clinical impact remain incompletely understood. We assessed
diaphragm strength in mechanically ventilated medical ICU patients, correlated the development of diaphragm
weakness with multiple clinical parameters, and examined the relationship between the level of diaphragm
weakness and patient outcomes.
Methods: Transdiaphragmatic twitch pressure (PdiTw) in response to bilateral magnetic stimulation of the phrenic
nerves was measured. Diaphragm weakness was correlated with the presence of infection, blood urea nitrogen,
albumin, and glucose levels. The relationship of diaphragm strength to patient outcomes, including mortality and
the duration of mechanical ventilation for successfully weaned patients, was also assessed.
Results: We found that infection is a major risk factor for diaphragm weakness in mechanically ventilated medical
ICU patients. Outcomes for patients with severe diaphragm weakness (PdiTw <10 cmH2O) were poor, with a
markedly increased mortality (49%) compared to patients with PdiTw ≥10 cmH2O (7% mortality, P = 0.022). In
addition, survivors with PdiTw <10 cmH2O required a significantly longer duration of mechanical ventilation (12.3 ±
1.7 days) than those with PdiTw ≥10 cmH2O (5.5 ± 2.0 days, P = 0.016).
Conclusions: Infection is a major cause of severe diaphragm weakness in mechanically ventilated patients.
Moreover, diaphragm weakness is an important determinant of poor outcomes in this patient population.

Introduction
The number of mechanically ventilated patients in medical ICUs (MICUs) in the United States has increased
dramatically over the past 20 years. Currently 800,000
patients per year require mechanical ventilation [1].
Many of these patients die, with an annual mortality
exceeding 200,000 [2]. In addition, survivors often
require prolonged, expensive hospital stays to achieve
liberation from mechanical ventilation [3]. In the past it
was thought that the severity of lung disease was the
major determinant of outcomes in MICU patients, but
recent work indicates that mechanically ventilated
patients develop significant diaphragm weakness [4-6].
Diaphragm weakness is primarily thought to occur as a
consequence of ventilator-induced diaphragm inactivity,
* Correspondence: gsupi2@email.uky.edu
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with weakness progressing as duration of mechanical
ventilation increases [7,8]. Theoretically, however, there
are other mechanisms by which diaphragm weakness
can develop. Animal studies indicate that experimental
models of infection induce significant diaphragm weakness [9,10]. In addition, data suggest that azotemia,
hyperglycemia, and low systemic albumin levels are risk
factors for prolonged mechanical ventilation and could
theoretically be associated with the development of
respiratory muscle weakness [11-13]. The importance of
infection, azotemia, hyperglycemia, and reduced albumin
levels as risk factors for the development of diaphragm
weakness in mechanically ventilated patients, however, is
unknown.
Diaphragm weakness is also commonly thought to predispose patients to sustained respiratory failure, greatly
prolonging the time required to wean patients from
mechanical ventilation and worsening clinical outcomes.
No previous study, however, has examined the quantitative relationship of diaphragm function, assessed using a
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purely objective, nonvolitional technique (such as bilateral anterior magnetic phrenic nerve stimulation), to clinical outcomes in mechanically ventilated patients.
The purpose of the present study, therefore, was to
objectively measure diaphragm strength in a crosssection of mechanically ventilated MICU patients and to
test the specific hypothesis that the severity of diaphragm weakness would correlate with one or more of
the following clinical factors: the presence of infection,
blood urea nitrogen level, serum albumin level, and/or
blood glucose level. We also ascertained the relationship
of diaphragm strength to patient outcomes, including
mortality, rate of transfer to long-term acute care
(LTAC) facilities, and the subsequent duration of
mechanical ventilation in MICU survivors who were
successfully extubated. Finally, to determine whether
clinicians were cognizant of the severity of diaphragm
weakness present in their patients, we asked the attending MICU physicians to estimate diaphragm strength
and compared these estimates with objectively determined measurements.

Methods
Study protocol

Studies were performed on adult ICU patients requiring
mechanical ventilation in the University of Kentucky
MICU for more than 24 hours. The protocol was
approved by the University of Kentucky Institutional
Review Board and informed consent was obtained from
subjects and their surrogates. The following were
recorded: diaphragm strength by measuring the transdiaphragmatic twitch pressure (PdiTw); respiratory static
system compliance and airway resistance using the
mechanical ventilator diagnostic module; basic clinical
data; clinician estimates of diaphragm strength; and outcomes, including mortality, rate of transfer to LTAC
facilities, and additional days required for continued
mechanical ventilation until successful extubation.
Exclusion criteria

If the attending physician anticipated that the patient
would be successfully weaned from mechanical ventilation in less than 24 hours, or determined that the
patient was too unstable to tolerate the measurements,
subjects were not screened for study inclusion. Exclusion criteria included: requirement for high dose pressors (≥15 μg/minute norepinephrine or ≥15 mg/kg/
minute dopamine); elevated positive end-expiratory
pressure (PEEP ≥15 cmH 2 O); presence of a cardiac
pacemaker or implanted defibrillator; administration of
neuromuscular blocking agents within 48 hours prior to
study entry; recent variceal bleeding; pregnancy; incarceration; or institutionalization.
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Determination of transdiaphragmatic twitch pressure

Diaphragm strength was assessed by measuring PdiTw
in response to bilateral anterior magnetic stimulation of
the phrenic nerves. PdiTw is an objective, nonvolitional
technique that has been verified in previous studies to
provide the most accurate assessment of diaphragm
strength in humans [14-16]. Moreover, previous studies
demonstrate that this technique can reliably and reproducibly measure diaphragm contractile strength in
mechanically ventilated ICU patients [4-6].
Subjects were studied in the supine position with the
head of the bed elevated at 30°. Two sterile commercially
available balloon-tipped catheters (Ackrad Laboratories,
NJ, USA) were passed through the nose after application
of local anesthetic (1 milliliter of 1% Lidocaine gel); one
catheter was placed in the stomach, while the other was
placed in the esophagus. Following initial placement, the
catheters were connected to Validyne pressure transducers (Validyne Engineering, Northridge, CA, USA) to
verify correct positioning. Correct placement of the gastric balloon was confirmed by demonstrating a positive
pressure in response to pressure applied over the stomach; correct placement of the esophageal balloon was
verified by demonstrating that the pressure waveform
had an end-expiratory pressure similar to the total PEEP
level and also mirrored airway pressure changes with
inspiratory efforts during airway occlusion.
After confirming accurate balloon placement, subjects
were left to breathe quietly for 10 minutes before
further assessment. Figure of eight magnetic coils
attached to dual Magstim 200 stimulators (Jali Medical,
Inc., Waltham, MA, USA) were then placed bilaterally
over the phrenic nerves adjacent to the border of the
sternocleidomastoid muscles. Magnetic field strength
was adjusted to maximal levels (100%) and simultaneous
supramaximal magnetic pulses were delivered to the
phrenic nerves bilaterally to elicit maximal twitch transdiaphragmatic pressures (that is, PdiTw). Stimuli were
interpolated between adjacent ventilator breaths and the
transdiaphragmatic pressures elicited by these stimuli
were recorded while simultaneously and transiently
occluding the external circuit connecting the endotracheal tube to the ventilator with a pneumatic valve. A
minimum of five twitches were recorded, with at least
30 seconds between adjacent stimuli. To verify stimuli
were supramaximal, additional twitches were performed
at reduced magnetic field strengths (90 to 95%). PdiTw
was calculated as follows:
pdiTw =  gastric pressure −  esophageal pressure

The best three measurements in response to 100%
levels of magnetic stimulation were averaged for each
subject and recorded as the PdiTw.
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Measurement of respiratory system static compliance and
airway resistance

For these assessments, the ventilator was set to a
square-wave flow pattern with an inspiratory plateau.
The ventilator rate was then transiently increased (for
example, 30 to 60 seconds) to suppress spontaneous
respirations. After reaching a steady state, the peak pressure and the plateau pressure were recorded and intrinsic PEEP was determined using an end-expiratory
occlusion maneuver. Inspiratory airway resistance of the
respiratory system was calculated as:

(Peak pressure - plateau pressure) inspiratory flow
The effective static compliance of the respiratory system was calculated as:

Tidal volume (plateau pressure − (total PEEP))
Once measurements were completed, the ventilator
was returned to its previous mode and settings.
Clinical parameters

Data for the following clinical parameters were collected
as close as possible to the time of determination of
PdiTw levels: age, gender, clinical diagnoses, the presence of positive cultures for infectious agents, antibiotic
regimen, glucose, albumin, blood urea nitrogen (BUN),
Sequential Organ Failure Assessment scores, Charlson
comorbidity indexes, vital signs, duration of mechanical
ventilation prior to PdiTw measurement, mechanical
ventilation mode, FiO2 (fraction of inspired oxygen),
tidal volume and rate, percentage of patient triggered
breaths, and most recent arterial blood gas values. All
recorded values were obtained within 24 hours of
PdiTw assessment.
Clinician estimates

Attending physicians were asked to estimate the level of
diaphragm strength using a form with qualitative descriptors of muscle weakness (see Additional file 1).
Statistical analysis

Whenever data were normally distributed and variances
were similar, parametric tests were used to compare
groups. When these conditions were not met, nonparametric tests were used to make comparisons. Data analyzed
using parametric tests are presented as mean ± standard
error of the mean. Data analyzed using nonparametric tests
are presented as median ± confidence intervals. Linear
regression was utilized to assess the relationship of BUN,
albumin, glucose and duration of prior mechanical ventilation to PdiTw level. Analysis of variance was employed to
compare PdiTw across cohorts of patients with different
levels of ventilator triggering. Fisher exact testing and
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receiver operating curve analyses were used to determine
the boundary between weak and strong PdiTw groups that
best discriminated between survival and mortality [17].

Results
Diaphragm strength in medical ICU patients

Sixty subjects were recruited into the study. PdiTw could
not be measured in three subjects because the magnetic
coils could not be effectively positioned due to anatomic
constraints (Subjects 18, 43, and 48). Detailed information for the 57 subjects in whom PdiTw measurements
were successfully performed is provided in Additional
file 2. To verify that we achieved supramaximal levels of
magnetic stimulation, we plotted the PdiTw values
achieved using 95% magnetic field strength levels against
PdiTw values attained using 100% magnetic field
strength, as shown in Figure 1A. The PdiTw levels
obtained using 95% and 100% field strength levels were
virtually identical, arguing that supramaximal neural stimulation was achieved when employing 100% magnetic
field strength for these studies. Moreover, the twitch
determinations were highly reproducible in individual
subjects, with a coefficient of variation for the best three
measurements performed at 100% stimulator output
averaging 7% for the 57 subjects. High levels of PEEP can
alter the relationship between the actual intrinsic diaphragm strength and the measured PdiTw. In the present
cohort of patients, however, only one study subject had
PEEP >8 cmH2O. As a result, PEEP-induced hyperinflation did not appreciably impact our data analysis (see
Additional file 3).
This cohort of 57 mechanically ventilated subjects had a
mean PdiTw of 7.9 ± 0.6 cmH2O. This value is similar
to values reported previously in mechanically ventilated
critically ill patients [4-6]. For comparison, normal
healthy adults average a PdiTw of 29.3 ± 2.8 cmH2O in
our laboratory; this value is similar to that reported for
healthy adults in the literature [4,14]. Estimates of diaphragm strength from the attending physicians were
obtained for 51 subjects. Clinicians did not accurately
predict the level of diaphragm strength of their patients
(Figure 1B). In many cases, patients with profound levels
of diaphragm weakness were thought to have normal
strength. Strength was overestimated in 46 of 51
patients, was correctly estimated in five patients, and
was never underestimated.
Risk factors for the development of diaphragm weakness

Data were analyzed to determine which factors correlated
with the level of diaphragm weakness in mechanically ventilated subjects. We found a strong relationship between
the presence of infection and diaphragm weakness. In all,
41 subjects were classified as being infected based on a
positive test for a pathogenic organism from a sterile site
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Figure 1 Transdiaphragmatic twitch pressure: measured levels and physician estimates. (A) Transdiaphragmatic twitch pressure (PdiTw)
levels for the 57 subjects included in the analysis. Each symbol represents a single subject and plots the PdiTw level obtained in response to
stimulation of the phrenic nerves with 95% of maximum magnetic field strength (y axis) against the PdiTw obtained in response to stimulation
of the phrenic nerves with 100% of maximum magnetic field strength (x axis). All data cluster along the line of identity, indicating that
supramaximal stimulation was achieved during 100% magnetic field stimulation. If supramaximal conditions had not been achieved, data points
would have fallen to the right of the line of identity. (B) Measured PdiTw levels compared with levels predicted for each subject by their
attending physicians; each symbol represents data from a single patient. Red symbols below the line (46 out of 51 determinations) indicate
determinations for which physicians overestimated diaphragm strength (that is, PdiTw).

(40 patients) or a clinical diagnosis of bacterial pneumonia
(one patient; cultures were lost for this individual). All 41
subjects classified as infected were thought by the attending physicians who were providing care for these patients
to be infected clinically and all 41 of these patients
received antibiotic therapy (Tables 2 and 3). The
remaining 16 patients were classified as non-infected
(see Table 2). Infected patients had a median PdiTw of
only 5.5 cmH2O (25 to 75% confidence levels of 4.0 to
7.9 cmH2O), while patients without clinical evidence of
infection had a median PdiTw of 13.0 cmH 2 O (25
to 75% confidence levels of 11.0 to 14.7, P < 0.001)
(Figure 2A). Of interest, while infection was associated
with greater diaphragm weakness, infected patients did
not have significantly different respiratory mechanical
parameters (that is, respiratory system static compliance and airway resistance) from non-infected patients
(Figure 2B, C).

We also found that there was no significant correlation
between PdiTw and either BUN, albumin, or glucose levels
(Figures 3A, B, C). While many patients were receiving
steroids (regimens provided in Table 3), we found no correlation between steroid dosage and PdiTw values (see
Additional file 4). In addition, we found no relationship
between the number of days subjects had been on
mechanical ventilation prior to testing and the level of
PdiTw (Figure 4A). This finding contrasts with recent
reports suggesting that patients on mechanical ventilation
for longer durations have progressively lower levels of diaphragm strength [6,18]. One potential explanation for this
difference is that the patients examined in the present
study were all ventilated with assist modes of mechanical
ventilation, while previous work that demonstrated a
strong relationship between mechanical ventilation and
the development of diaphragm weakness specifically
restricted examination to patients who were on controlled
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Table 1 Characteristics of non-infected and infected
study subjects

Age (years)

Non-infected
(n = 16)

Infected
(n = 41)

52.4 ± 14.1

55.5 ± 16.7

Gender (%)
Male

44

49

Female
Body mass index

56
30.3 ± 9.2

51
29.8 ± 9.5

Total ICU days

15.1 ± 9.8

34.9 ± 40.2

Days of MV before PdiTw
measurement

9.1 ± 8.9

10.4 ± 12.4

Steroid usage (%)

50

51

Data presented as mean ± standard deviation. MV, mechanical ventilation;
PdiTw, transdiaphragmatic twitch pressure.

mechanical ventilation with little or no spontaneous
respiratory activity [18]. As shown in Figure 4B, our
patient population had a high level of spontaneous respiratory activity, with the majority of patients triggering more
than 75% of ventilator breaths. Of interest, we also found
that PdiTw was similar over the range of levels of ventilator triggering observed in the present study (Figure 4C).
Relationship of diaphragm strength to patient outcomes

To assess the relationship between diaphragm strength
and mortality, we plotted PdiTw against patient days of
survival (Figure 5A). Patients that died were significantly
weaker than survivors, with PdiTw averaging 6.3 ± 0.6
and 8.9 ± 0.9 cmH2O, respectively, for these two groups
(P < 0.04). To further analyze this relationship, we used
Fisher exact testing and ROC curve analyses to determine the level of PdiTw that best discriminated between
survival and mortality [17]. Both forms of testing found
this boundary to be 10 cmH 2 O. Patients with PdiTw
≥10 cmH2O had only a 7% mortality (one death out of
14 patients) while patients with PdiTw <10 cmH2O had
a 49% mortality (17 deaths out of 35 patients, P = 0.022
for comparison of the two groups; Figure 5B). Because
indices of lung function may influence mortality, we
also compared respiratory system static compliance and
airway resistance between patients with PdiTw ≥10
cmH2O and patients with Pdi <10 cmH2O (Figures 5C, D).
Lung mechanics were not significantly different between
these two groups of patients, indicating that level of diaphragm function, not lung function, best correlated with
survival in our patients. In addition, patients with PdiTw
≥10 cmH2O and PdiTw <10 cmH2O had similar Sequential
Organ Failure Assessment scores (7.6 ± 0.6 and 6.9 ± 0.4,
respectively) and Charlson Comorbidity Indices (2.7 ± 0.5
and 2.5 ± 0.3, respectively).
We also evaluated the possible mechanism(s) by which
diaphragm weakness may have influenced the incidence
of death. In this cohort, five of the patients with PdiTw

<10 cmH2O that died were receiving vasopressors when
care was withdrawn; vasopressors and mechanical ventilation were stopped simultaneously in these patients and
death occurred as a result of combined respiratory failure and hypotension. In the remaining 12 patients with
PdiTw <10 cmH 2 O that died, none met criteria for
brain death, all maintained motor drive to the respiratory pump, none were on vasopressors, and the only
form of continuous life support that these patients were
receiving was mechanical ventilation. Prior weaning
trials had been attempted and all 12 patients had failed
to reach extubation criteria. Death occurred in these 12
patients when mechanical ventilation was withdrawn.
These data suggest that the presence of severe diaphragm weakness limited weaning trial success in these
12 patients and may have influenced the decision to
withdraw care.
With respect to other outcome measures, seven patients
with PdiTw <10 cmH2O were transferred to a long-term
ventilator facility while only one of the patients with
PdiTw ≥10 cmH2O was transferred to a LTAC facility. In
addition, the time required to wean survivors from
mechanical ventilation was a function of PdiTw, with time
to wean increasing significantly for patients with PdiTw
<10 cmH2O (Figure 6A). On average, duration of mechanical ventilation after PdiTw measurements was 12.3 ± 1.7
days for patients with PdiTw <10 cmH2O but only 5.5 ±
2.0 days for patients with PdiTw ≥10 cmH2O (P = 0.016).
In contrast, duration of mechanical ventilation had no
relationship to either respiratory system static compliance
(Figure 6B) or airway resistance (Figure 6C).

Discussion
The present study indicates that diaphragm weakness is a
significant determinant for poor outcomes in mechanically ventilated MICU patients We found that the incidence of death was 49% in the patients with the weakest
diaphragms (that is, with PdiTw <10 cmH 2 O) but was
only 7% for patients with PdiTw levels ≥10 cmH2O. One
possible explanation for the far greater mortality in
patients with PdiTw <10 cmH2O could be that weakness
is simply a marker for multiorgan system failure and that
damage to these other organs was primarily responsible
for patient deaths. Surprisingly, however, we found that
indices of disease severity (for example, lung mechanics,
Sequential Organ Failure Assessment scores, Charlson
Comorbidity Indexes) were almost identical in patients
with PdiTw levels ≥10 cmH 2 O and in patients with
PdiTw <10 cmH 2 O, suggesting that the relationship
between diaphragm weakness and mortality is not simply
an epiphenomenon. Moreover, the majority of patient
deaths (12 of 18 deaths) were the direct result of withdrawal of mechanical ventilatory support in weak patients
and, in each case, occurred after unsuccessful weaning
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Table 2 Classification of subjects according to presence/absence of active infection at time of PdiTw measurementsa
Subject
number

Infected Site

Organism(s) isolated from site(s)

Diagnosis of infection by
attending physician

1

No

2

Yes

3
4

No
Yes

5

No

6
7

No

No

No

Liver abscess

Staphylococcus sp., Fusobacterium
necrophorum

Yes

Yes

Yes

PAL

Streptococcus pneumonia

No
Yes

No
Yes

No
Yes

No

No

No

Yes

Blood

Gram-positive bacteriac

Yes

Yes

Yes

Yes

PAL

Pseudomonas aeruginosa

Yes

Yes

Yes

8

Yes

Blood

Staphylococcus species

9

No

10

Yes

11
12

No
Yes

PAL
Sinuses
Nasopharyngeal
swab

Pseudomonas aeruginosa
Bacteroides capillosus, Fusobacterium
sp., b-strep. Gp C
Influenza A

13

No

14

Yes

Jejunal drain

VRE, Pseudomonas aeruginosa

Blood

Staphylococcus aureus

15

Yes

16

No

17

Yes

PAL

Staphylococcus species

Blood

Staphylococcus species

Antibiotic
therapyb

Pulmonary
infiltrates

Yes

Yes

Yes

No

No

Yesd

Yes

Yes

Yes

No
Yes

No
Yes

No
Yes

No

No

No

Yes

Yes

Yes

Yes

Yes

No

No

No

No

Yes

Yes

Yes

19

Yes

PAL

Klebsiella pneumonia

Yes

Yes

Yes

20
21

Yes
Yes

Blood
Neck abscess

Staphylococcus aureus
Streptococcus sp.

Yes
Yes

Yes
Yes

No
No

22

Yes

Sputum

Hemophilus parainfluenza

Yes

Yes

Yes

23

Yes

Stage IV
decubitus

Pseudomonas aeruginosa, Proteus
mirabilis

Yes

Yes

No

Urine

Pseudomonas aeruginosa

24

No

No

No

No

25

No

No

No

No

26

No

27

Yes

No

No

No

Subphrenic
abscess

Candida glabrata

Yes

Yes

Yes

No

No

No

BAL

Escherichia coli, Klebsiella pneumoniae

Yes

Yes

Yes

No
No
Yes

No
Yesd
No
Yes

28

No

29

Yes

30
31
32

No
No
Yes

Blood

Enterococcus faecalis

No
No
Yes

33

Yes

PAL

Staphylococcus aureus

Yes

Yes

34

Yes

Blood

Gram-positive coccic

Yes

Yes

Yes

35

Yes

ET aspirate

Acinetobacter calcoaceticus,
Enterobacter cloacae

Yes

Yes

Yes

Blood

Candida

36

Yes

Yes

Yes

Yes

PAL

Achromobacter xyloxosidans

Central venous
catheter

Pseudomonas aeruginosa

37

Yes

PAL

Pseudomonas aeruginosa

Yes

Yes

Yes

38
39

Yes
Yes

Liver abscess
PAL

Escherichia coli
Staphylococcus sp., Enterobacter
aerogenes, Escherichia coli

Yes
Yes

Yes
Yes

Yes
Yes

40

Yes

PAL
Blood

MRSA
MRSA

Yes

Yes

Yes
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Table 2 Classification of subjects according to presence/absence of active infection at time of PdiTw measurementsa
(Continued)
41

Yes

42

Yes

Nasopharyngeal
swab

Influenza B

Yes

Yes

Yes

Yes

Yes

Yes

Yesd

Blood

MRSA

Leg abscess

MRSA

Osteomyelitis

MRSA

44

No

No

No

45

No

No

No

No

46

Yes

Sputum

MRSA

Yes

Yes

Yes

47
49

Yes
No

PAL

Streptococcus pneumonia

Yes
No

Yes
No

Yes
No

50

Yes

Pleural fluid

Acinetobacter baumannii, VRE

Yes

Yes

Yes

Pleural tissue

Acinetobacter baumannii, VRE

51

Yes

Blood

Bacillus circulans

Yes

Yes

Yes

52

Yes

Blood

VRE

Yes

Yes

Yes

53

Yes

Yes

Yes

Yes

Yes

Yes

Yes

54

PAL

Pseudomonas aeruginosa

Nasopharyngeal
swab

H1N1

Yes

Blood

VRE

Yes

Yes

Yes

Yes

Yes

Yes

55

Yes

Tracheal aspirate Stenotrophomonas maltophilia
PAL
MRSA

56

Yes

Blood

MRSA, Pseudomonas aeruginosa, VRE

Sputum

Pseudomonas aeruginosa

57
58

Yes
Yes

BAL
Samples loste
Tracheal aspirate Hemophilus influenza

Yes

Yes

Yes

Yes

Yes

Yes

59

Yes

Blood

Staphylococcus species

Yes

Yes

No

60

Yes

Urine

Enterobacter cloacae

Yes

Yes

Yes

PAL

Streptococcus sp.

a

Data not included for Subjects 18, 43, and 48 because transdiaphragmatic twitch pressure (PdiTw) measurements were not obtained due to anatomic
constraints. bPatient on antibiotic therapy at the time of PdiTw measurement. cOrganism not speciated - subject treated with antibiotics prior to transfer.dPatient
with pulmonary infiltrates but without evidence of infection (Subject 9 with nonpulmonary acute lung injury, Subject 31 with pulmonary fibrosis, Subject 44 with
acute respiratory distress syndrome). eBronchoscopy performed with purulent exudates noted; specimens lost in transit to laboratory. BAL, bronchoalveolar
lavage; MRSA, methicillin-resistant Staphylococcus aureus; PAL, protected alveolar lavage; VRE, Enterococcus faecium (vancomycin-resistant).

Table 3 Medication regimen in 57 subjects at the time of transdiaphragmatic twitch pressure measurementsa
Subject Antibiotics
number

Other medications

1

Midazolam, metoprolol, hydralazine, calcium acetate,
famotidine

2

Piperacillin/tazobactam,
vancomycin, levofloxacin,
flagyl

Enoxaparin, omeprazole, dobutamine

Piperacillin/tazobactam,
vancomycin, levofloxacin

Midazolam, fentanyl, pantoprazole

3
4

Hydrocortisone 100 mg every 8 hours × 4 days

Metoprolol, haloperidol, insulin, aspirin

5

6

Steroid regimen over entire ICU stay

Famotidine, trazadone

7

Piperacillin/tazobactam,
vancomycin, fluconazole
Piperacillin/tazobactam

8

Vancomycin

Midazolam, fentanyl, insulin, lactulose, levothyroxine,
norepinephrine, pantoprazole
Midazolam, alprazolam, fentanyl, insulin, famotidine,
heparin
Midazolam, fentanyl, insulin, famotidine, heparin,
simvastatin, gabapentin, venlafaxine, calcium
gluconate

Methylprednisolone 1 g/day × 3 days, prednisone
60 mg/day × 2 days, 40 mg/day × 3 days, 30 mg/day ×
2 days, 20 mg/day × 2 days, 10 mg/day × 2 days
Hydrocortisone 50 mg every 6 hours × 1 day

Hydrocortisone 50 mg every 8 hours × 8 days
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Table 3 Medication regimen in 57 subjects at the time of transdiaphragmatic twitch pressure measurements a
(Continued)
9

10

Piperacillin/tazobactam,
vancomycin

Midazolam, lorazepam, omeprazole, ursodiol,
clonidine, levetiracetam, ondansetron,
metaclopramide, hydralazine, heparin
Midazolam, famotidine, aspirin, clopidogrel, insulin,
heparin, metaclopramide, docusate
Midazolam, protonix, amitryptyline, bupropion,
carvedilol, clonazepam, folic acid, acetaminophen,
digoxin, ondansetron, heparin, tacrolimus

Vancomycin, clindamycin,
tamiflu

Midazolam, fentanyl, morphine, heparin, insulin,
pantoprazole, bumetanide

11

12
13

Vancomycin, levofloxacin,
flagyl, aztreonam

Midazolam, fentanyl, heparin

15

Vancomycin

Propofol, omeprazole, heparin, amlodipine

16

Methylprednisolone 60 mg every 12 hours × 6 days

Midazolam, fentanyl, protonix, ondansetron,
darbepoetin, folic acid, cyanocobalamin, hydralazine,
amldipine, lisinopril

17

Vancomycin, levofloxacin

Midazolam, fentanyl, protonix, insulin, lactulose,
levothyroxine, sertraline, hydralazine, gabapentin,
carvedilol

19

Vancomycin, piperacillin/
tazobactam, levofloxacin

Heparin, hydralazine, labetalol, metoprolol,
levetiracetam, lorazepam, omeprazole, phenytoin

20

Vancomycin

Midazolam, morphine, amlodipine, labetalol,
metoprolol, protonix, phenytoin, heparin

21

Vancomycin, tobramycin,
ampicillin/sulbactam

Midazolam, fentanyl, heparin, ibuprofen, amiodarone,
metoprolol, omeprazole

22

Vancomycin, levofloxacin

Famotidine, heparin, metaclopramide,
diphenhydramine

23

Vancomycin, doripenem,
colistin

Bumetanide, midazolam, ascorbic acid, famotidine,
insulin, vitamin A, zinc, aripiprazole, escitalopram,
heparin

24

Paroxetine, pramipexole, simvastatin, omeprazole,
heparin, midazolam, insulin, metoprolol, bumetanide

25

Midazolam, heparin, omeprazole, haloperidol,
olanzapine, insulin

26

Famotidine, darbepoetin, amlodipine, labetolol, folic
acid, thiamine, dexmedetomidine, heparin
Midazolam, fentanyl, promethazine, pantoprazole,
levetiracetam, propofol, lactulose
Midazolam, haloperidol, omeprazole, levothyroxine,
heparin, insulin, furosemide
Morphine, ondansetron, rifaximin, pantoprazole,
lactulose, insulin, aspirin, heparin, levetriacetam,
midazolam, phenytoin, vasopressin

Doripenem, doxycycline,
micafungin, flagyl

28
29

Methylprednisolone 60 mg/day × 4 days, prednisone
40 mg/day × 3 days

Midazolam, enoxaparin, famotidine, insulin,
metoprolol, aspirin, hydralazine, lisinopril, simvastatin

14

27

Prednisone 20 mg/day × 3 days, Hydrocortisone
100 mg every 8 hours × 2 days
Methylprednisolone 60 mg every 12 hours × 3 days

Doripenem, tobramycin,
fluconazole, erythromycin

Prednisone 20 mg/day × 2 days

Prednisone 40 mg/day × 6 days

Prednisone 50 mg every 8 hours × 8 days

30

Aspirin, benztropine, famotidine, gabapentin,
Methylprednisolone 125 mg every 6 hours × 2 days
hydrochlorothiazide, metoclopramide, miralax, insulin,
heparin, valproic acid, docusate

31

Azathioprine, bumetanide, clopidogrel, ezetimibe,
famotidine, fentanyl, furosemide, heparin, metoprolol,
midazolam, nitroglycerin patch, omeprazole,
provastatin

Methylprednisilone 125 mg every 6 hours × 3 days,
40 mg every 6 hours × 2 days, prednisone
60 mg/day × 5 days
Methylprednisolone 60 mg every 6 hours × 6 days

32

Vancomycin, gentamycin,
aztreonam

Midazolam, fentanyl, aspirin, carbemazepam,
haloperidol, metoprolol, omeprazole, phenytoin,
insulin, heparin

33

Linezolid

34

Vancomycin, piperacillin/
tazobactam, micofungin
Vancomycin, piperacillin/
tazobactam, micofungin,
colistin, bactrim

Midazolam, lorazepam, fentanyl, aspirin, digoxin,
insulin, metoprolol, famotidine, heparin
Midazolam, fentanyl, insulin, aspirin, amlodipine,
metaclopramide, famotidine, heparin
Foscarnate, pantoprazole, diphenhydramine, insulin,
fludrocortisone, levothyroxine, ursodiol

35

Methylprednisolone 100 mg every 12 hours × 9 days
Methylprednisolone 10 mg × 1 day
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Table 3 Medication regimen in 57 subjects at the time of transdiaphragmatic twitch pressure measurements a
(Continued)
36

Vancomycin,
meraopenum,
valgancyclovir, cefipime,
dapsone, levofloxacin

Ondansetron, omeprazole, metoprolol,
mycophenolate mofetil, sildenafil

Prednisone 25 mg/day × 250 days

37

Piperacillin/tazobactam,
vancomycin, levofloxacin

Midazolam, fentanyl, aspirin, heparin, omeprazole,
simvastatin

Methylprednisolone 40 mg/day × 2 days, prednisone
40 mg/day × 1 day, prednisone 20 mg/day × 3 days

38

Flagyl, levofloxacin,
aztreonam

Midazolam, fentanyl, morphine, norepinephrine,
vasopressin, famotidine, heparin

39

Doripenam, colistimethate, Midazolam, fentanyl, lortab, zolpidem, metoprolol,
vancomycin
omeprazole, heparin

40

Vancomycin, piperacillin/
tazobactam, levofloxacin

Midazolam, fentanyl, metaclopramide, aspirin,
azathioprine, clopidogrel, furosemide, ondansetron,
simvastatin, famotidine, heparin

41

Vancomycin, piperacillin/
tazobactam, clindamycin

Midazolam, fentanyl, propofol, insulin, omeprazole

42

Vancomycin, cefipime,
levofloxacin, acyclovir

Midazolam, fentanyl, ondansetron, pantoprazole,
heparin

Prednisone 20 mg/day × 7 days

44

Midazolam, fentanyl, haloperidol, insulin, famotidine,
heparin

Methylprednisolone 125 mg every 6 hours × 2 days

45

Midazolam, fentanyl, ondansetron, insulin,
omeprazole, heparin

Hydrocortisone 100 mg every 8 hours × 3 days

46

Linezolid, piperacillin/
tazobactam, tobramycin

Midazolam, Diltiazem, mycophenolate mofetil,
tacrolimus, famotidine, insulin, heparin

Hydrocortisone 100 mg every 8 hours × 6 days,
prednisone 40 mg/day × 3 days

47

Vancomycin, cefipime,
levofloxacin

Midazolam, aspirin, captopril, furosemide, simvastatin,
insulin

Prednisone 40 mg/day × 3 days, 30 mg/day × 2 days

Midazolam, aspirin, atorvastatin, bisoprolol,
clopidogrel, fluticasone, folic acid, pantoprazole,
heparin

Methylprednisolone 60 mg every 6 hours × 4 days,
40 mg every 12 hours × 2 days, prednisone
40 mg/day × 1 day

Midazolam, hydroxyzine, darbepoetin, levothyroxine,
ferrous sulfate, ergocalciferol, pancrelipase,
omeprazole
Midazolam, fentanyl, furosemide, pancrelipase,
magnesium oxide, famotidine, insulin, heparin

Hydrocortisone 20 mg every 12 hours × 37 days

Hydrocortisone 100 mg every 8 hours × 5 days

49

50

Vancomycin, aztreonam,
tobramycin, daptomycin

51

Vancomycin, piperacillin/
tazobactam, doripenam,
fluconazaole

52

Vancomycin, piperacillin/
tazobactam, daptomycin

Midazolam, fentanyl, levothyroxine, darbepoetin,
fluticasone, lactulose, paroxetime, insulin, heparin

53

Tamiflu, piperacillin/
tazobactam, cefipime,
daptomycin, doripenam

Midazolam, darbepoetin, bumetanide, famotidine,
insulin, heparin

54

Vancomycin, piperacillin/
tazobactam

Morphine, oxycodone, furosemide, famotidine, insulin, Hydrocortisone 50 mg every 6 hours × 3 days
heparin

55

Vancomycin, piperacillin/
tazobactam, levofloxacin,
daptomycin

Ferrous sulfate, folic acid, levothyroxine,
metaclopramide, pravastatin, digoxin tacrolimus,
omeprazole, heparin

56

Daptomycin, linezolid,
tobramycin, colistin,
zithromax

Midazolam, fentanyl, dexmedetomidine, omeprazole,
heparin

57

Vancomycin, piperacillin/
tazobactam, levofloxacin,
tamiflu
Piperacillin/tazobactam

Midazolam, fentanyl, clonazepam, gabapentin,
famotidine, insulin, heparin

58

Midazolam, morphine, furosemide, metoprolol,
citalopram, pantoprazole, aspirin, acetazolamide,
insulin, heparin

59

Vancomycin, cefipime,
levofloxacin

Midazolam, fentanyl, dopamine, norepinephrine,
simvastatin, aspirin, omeprazole, heparin

60

Vancomycin, cefipime,
tobramycin

Midazolam, fentanyl, norepinephrine, pantoprazole,
heparin

a

Methylprednisolone 60 mg every 8 hours × 4 days,
prednisone 60 mg/day × 5 days, 40 mg/day ×
5 days, 30 mg/day × 5 days
Hydrocortisone 100 mg every 8 hours × 3 days, 50
mg every 8 hours × 2 day, 50 mg every 12 hours ×
7 days

Data not included for Subjects 18, 43, and 48 because transdiaphragmatic twitch pressure measurements not obtained due to anatomic constraint.
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Figure 2 Infection and diaphragm weakness. (A) Transdiaphragmatic twitch pressure (PdiTw) measurements for non-infected and infected
patients. Data from individual patients are shown for each group on the right, while plots on the left for each group show mean (filled squares),
median levels (middle line of box), 25% and 75% confidence intervals (upper and lower borders of the box) and 1% and 99% intervals (whiskers
above and below the box). Infection was associated with significant lower Pdi Twitch values (*statistical significance). (B) respiratory system (RS)
static compliance and (C) inspiratory airway resistance for non-infected and infected patients; there was no difference in these indices of lung
function between non-infected and infected groups.
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Figure 3 Correlation of transdiaphragmatic twitch pressure to blood urea nitrogen, albumin, and glucose levels. Transdiaphragmatic
twitch pressure (PdiTw) as a function of (A) blood urea nitrogen (BUN), (B) albumin, and (C) glucose levels. There was no significant correlation
between any these parameters and PdiTw. Specifically, correlation coefficients and P values for regression of PdiTw to parameters were,
respectively, 0.146 and 0.277 for BUN, 0.072 and 0.596 for albumin, and 0.032 and 0.815 for glucose levels (all nonsignificant).

Supinski and Ann Callahan Critical Care 2013, 17:R120
http://ccforum.com/content/17/3/R120

Page 12 of 17

Figure 4 Relationship of prior duration of mechanical ventilation and ventilator triggering to diaphragm strength.
(A) Transdiaphragmatic twitch pressure (PdiTw) as a function of the duration of mechanical ventilation prior to measurement of PdiTw. There
was no statistically significant correlation of PdiTw to duration of ventilation prior to measurement, with a correlation coefficient of 0.020 and
P = 0.881 for this assessment (nonsignificant). (B) The majority of subjects actively initiated (that is, triggered) ventilator breaths more than 75%
of the time. (C) The level of diaphragm strength (PdiTw) did not correlate with the level of triggering, with the same PdiTw observed at all
triggering levels.
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Figure 5 Relationship of diaphragm strength to survival. (A) Survival of patients (days after measurement, x axis) as a function of
transdiaphragmatic twitch pressure (PdiTw) level (y axis). Patients that died had low average PdiTw levels (6.3 ± 0.6 cmH2O) while survivors had
higher PdiTw levels (8.9 ± 0.9 cmH2O, P = 0.044). (B) Survival curves for subjects with PdiTw ≥10 cmH2O (n = 15) and PdiTw <10 cmH2O (n =
42). Weak subjects had a significantly higher mortality (49%) than strong subjects (7%, P = 0.022). To exclude the possibility that the greater
mortality in the weakest patients may have been due to the presence of more severe lung dysfunction, we also examined (C) respiratory system
(RS) static compliance and (D) airway resistance. There was no significant difference in RS static compliance or airway resistance for patients with
PdiTw ≥10 cmH2O and PdiTw <10 cmH2O, indicating that the greater mortality ion the weakest patients was not due to concomitant lung
dysfunction.
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Figure 6 Relationship of diaphragm strength to ventilator weaning duration. (A) Duration of mechanical ventilation after measurement of
transdiaphragmatic twitch pressure (PdiTw) as a function of the level of PdiTw; each symbol represents data from a single subject. Patients with
PdiTw ≥10 cmH2O required significantly shorter times to wean from mechanical ventilation when compared with patients with PdiTw <10
cmH2O (P = 0.016). The time required to wean from mechanical ventilation bore no relationship, however, to (B) the respiratory system (RS)
static compliance or (C) the airway resistance.

attempts. Weakness almost certainly contributed to the
inability to wean these patients from mechanical ventilation and thereby may have influenced the decision to
withdraw care.

We also found that a high percentage of patients with
PdiTw <10 cmH 2 O required transfer to LTAC units.
Reports indicate that long-term outcomes for this group
of patients are poor, with a high percentage (51%) dying
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within 1 year [19]. As a result, the high rate of transfer of
weak patients to these units represents a poor outcome.
In addition, we found that the relationship between diaphragm strength and duration of mechanical ventilation
for patients that did not die and remained in the ICU was
curvilinear, with duration increasing progressively as
PdiTw levels fell to lower values (Figure 6A). Weak
patients with PdiTw <10 cmH 2 O required more than
twice as long to wean from mechanical ventilation than
stronger patients with PdiTw levels ≥10 cmH2O. Moreover, the duration of mechanical ventilation did not correlate with the level of lung dysfunction but only with the
level of diaphragm strength.
We also evaluated our data to ascertain the role of
infections, BUN, albumin and glucose levels in the induction of diaphragm weakness in mechanically ventilated
patients. We found the level of diaphragm weakness in
mechanically ventilated MICU patients did not correlate
with BUN, glucose, or albumin levels despite previous
reports associating these factors with prolonged mechanical ventilation [11-13]. In contrast, we found that
evidence of infection was a predictor of strikingly lower
levels of diaphragm strength than that observed for noninfected patients. This finding is consistent with multiple
previous animal studies demonstrating that infection
rapidly reduces diaphragm force generation, decreases
diaphragm mitochondrial function, activates diaphragm
proteolytic pathways, and reduces diaphragm contractile
protein function [9,20-26].
While infected patients had the weakest diaphragms,
even the non-infected mechanically ventilated patients in
our study had a median level of PdiTw (13 cmH 2 O),
which is substantially lower than that observed for normal healthy adults (30 cmH2O). There are at least two
potential explanations for the weakness observed in the
non-infected patients. First, many of the patients in our
study were chronically ill, with multiple comorbid conditions including heart failure, malignancy, liver and renal
diseases. Each of these entities has negative effects on
muscle function, and it is possible that the pre-intubation
muscle function of these patients may have been appreciably lower than that observed in normal subjects.
In addition, use of mechanical ventilation can result in
diaphragm inactivity and atrophy [27-30]. Numerous
animal studies have provided evidence of this phenomenon, and, more recently, several elegant studies indicate
that loss of diaphragm function occurs in patients who
are subjected to controlled mechanical ventilation with
minimal or no spontaneous respirations [18,27]. Our
patients were all ventilated using assisted modes of
mechanical ventilation and may therefore have had less
inactivity-induced diaphragm dysfunction than observed
in patient populations ventilated with controlled modes
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of mechanical ventilation. Nevertheless, it is still possible
that ventilator-induced inactivity contributed to the level
of diaphragm weakness observed in our non-infected
patients. As a corollary, the level of weakness observed
in our infected patients may represent the combined
effects of chronic illness, ventilator-induced inactivity,
and infection-induced diaphragm dysfunction.
One should note, however, that the non-infected
patients had a level of PdiTw (median of 13 cmH2O) that
was sufficiently high for this group of patients to be
expected to have good outcomes (that is, a low death rate
and an average wean time from mechanical ventilation of
about 5 days) according to the data presented in Figures 5
and 6. Only the infected mechanically ventilated patients,
as a group, had low enough PdiTw levels (median of 5.5
cmH2O) to expect poor outcomes (that is, a high mortality
and a protracted need for mechanical ventilation). These
data therefore argue that even if all of the diaphragm
weakness observed in our non-infected patients was a consequence of ventilator-induced inactivity, this level of
weakness alone would not be expected to result in poor
patient outcomes. Our data would instead suggest that
only the combination of ventilator-induced inactivity and
infection may produce sufficient diaphragm weakness to
negatively influence patient survival and duration of
mechanical ventilation.

Conclusions
In summary, we found that mechanically ventilated MICU
patients have severe diaphragm weakness, that the clinicians caring for these patients greatly underestimate the
severity of diaphragm weakness present, and that infections are a major risk factor for the development of diaphragm weakness in this population. We also found that
diaphragm weakness was associated with poor patient outcomes, including a significantly increased mortality, an
increased transfer to LTACs and a markedly longer duration required for weaning from mechanical ventilation.
Diaphragm weakness appears to be a major risk factor
for respiratory failure and death in mechanically ventilated MICU patients; theoretically, pharmacological
treatments that improve diaphragm strength should
reduce the duration of mechanical ventilation and
MICU mortality. Currently no such agents are used in
clinical practice, but recent experimental studies indicate
that pharmacological inhibition of selected cellular pathways can prevent diaphragm weakness in animal models
of critical illness [31,32]. There is an urgent need to
translate these pharmacological treatments from the
bench to the bedside in order to prevent or reverse diaphragm weakness in mechanically ventilated MICU
patients. Such therapies are likely to influence both
acute and long-term outcomes.
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Key messages
• Recent work indicates that many mechanically ventilated MICU patients have severe diaphragm weakness, but the causes and consequences of this
weakness remain controversial.
• The present study indicates that infection is a
major risk factor for development of diaphragm
weakness in MICU patients treated with assist
modes of mechanical ventilation.
• This work also demonstrates that the level of diaphragm weakness is a novel predictor of clinical outcomes; the weakest patients have a high mortality and
require prolonged durations of mechanical ventilation.
• This study indicates that clinicians underestimate
the severity of diaphragm dysfunction in mechanically ventilated critically ill patients.
Additional material
Additional file 1: presents additional methods.
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